China Approved 94 Cancer Drugs in 2020-25, Exceeding U.S. FDA's 87 Approvals

According to a study published in Health Affairs, China's National Medical Products Administration approved 94 new cancer drugs during 2020-25, exceeding the U.S. FDA's 87 approvals in the same period. The research, released on Monday, showed that China approved cancer medications at nearly three times the rate of the U.S. in 2025.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments